Cargando…

Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib

Detalles Bibliográficos
Autores principales:	Colagrande, S., Calistri, L., Campani, C., Dragoni, G., Lorini, C., Nardi, C., Castellani, A., Marra, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128785/ https://www.ncbi.nlm.nih.gov/pubmed/33320291 http://dx.doi.org/10.1007/s00330-020-07592-0

Ejemplares similares

CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib
por: Colagrande, S., et al.
Publicado: (2020)

Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients
por: Feng, Yu-Min, et al.
Publicado: (2015)

Luker bort feilkilder ved CERN
Publicado: (2010)

12th Seminar ved Norges Tekniske Universitetsbibliotek
por: Hegseth, Bjørn
Publicado: (1995)

Pedagogy of CLE and CLE as pedagogy: An interview with Ved Kumari
por: Vashist, Latika
Publicado: (2021)

CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients
por: Bernatz, Simon, et al.
Publicado: (2023)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Hva lærer vi om elektrosvak fysikk ved LEP?
por: Bugge, L
Publicado: (1995)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

John Cockcroft synger ut: Alvorlig feil ved verdens prioritetsliste
por: Barlaup, A
Publicado: (1962)

En studie av silisiumdetektorer for JETSET: eksperimentet ved CERN's LEAR
por: Widding, A R
Publicado: (1995)

Fokusering ved hjelp av magnetiske felt med alternerande gradient
por: Kjell, Johnsen
Publicado: (1954)

GHR knockdown enhances the sensitivity of HCC cells to sorafenib
por: Gao, Shuang, et al.
Publicado: (2020)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
por: Liang, Kung-Hao, et al.
Publicado: (2021)

C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Spesifikasjon og design av et utlesningssystem for et LHC-eksperiment ved CERN
por: Gaarder, P E
Publicado: (1994)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience
por: Straś, Wojciech, et al.
Publicado: (2021)

Etter leptontallsbrytende desintegrasjoner av $Z^{0}$ ved hjelp av et nevralt nett
por: Austeng, A
Publicado: (1996)

Management of spontaneous dissection and rupture of common iliac artery in vascular Ehlers-Danlos syndrome (VEDS)
por: Fraser, Simon, et al.
Publicado: (2022)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
por: Shrestha, Ritu, et al.
Publicado: (2021)

Repetition of Examination Due to Motion Artifacts in Horizontal Cone Beam CT: Comparison among Three Different Kinds of Head Support
por: Nardi, Cosimo, et al.
Publicado: (2017)

ABC-VED Analysis of a Drug Store in the Department of Community Medicine of a Medical College in Delhi
por: Anand, T., et al.
Publicado: (2013)

Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro
por: Dituri, Francesco, et al.
Publicado: (2020)

Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
por: Hajighasemlou, Saieh, et al.
Publicado: (2020)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC
por: Zhou, Wei, et al.
Publicado: (2022)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
por: Neve Polimeno, Maria, et al.
Publicado: (2015)

Fysikerne far gigantmaskine: 30 kilometers tunnelring ved CERN skali 1990erne huse antistof-kollisioner
Publicado: (1979)

ABC and VED Analysis of the Pharmacy Store of a Tertiary Care Teaching, Research and Referral Healthcare Institute of India
por: Devnani, M, et al.
Publicado: (2010)

Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
por: Campani, Claudia, et al.
Publicado: (2020)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
por: Lai, Hong-Yue, et al.
Publicado: (2021)

Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation
por: Piccinno, Emanuele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cv3hb3id6efa69k71eaisch4vv